147 related articles for article (PubMed ID: 20081590)
1. Slowing the progression of chronic kidney disease.
Herrington WG; Mason PD
Br J Hosp Med (Lond); 2009 Nov; 70(11):634-8. PubMed ID: 20081590
[TBL] [Abstract][Full Text] [Related]
2. Update on the management of chronic kidney disease.
Rivera JA; O'Hare AM; Harper GM
Am Fam Physician; 2012 Oct; 86(8):749-54. PubMed ID: 23062158
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of chronic kidney disease: therapeutic strategy].
Belenfant X; Tabbi Anani W; Roland M; Mavel MC; Laederich J
Presse Med; 2012 Mar; 41(3 Pt 1):304-10. PubMed ID: 22285135
[TBL] [Abstract][Full Text] [Related]
4. Progression of chronic kidney disease: can it be prevented or arrested?
Jaber BL; Madias NE
Am J Med; 2005 Dec; 118(12):1323-30. PubMed ID: 16378772
[TBL] [Abstract][Full Text] [Related]
5. The MAURO study: baseline characteristics and compliance with guidelines targets.
Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
[TBL] [Abstract][Full Text] [Related]
6. Clinical practice. Stage IV chronic kidney disease.
Abboud H; Henrich WL
N Engl J Med; 2010 Jan; 362(1):56-65. PubMed ID: 20054047
[No Abstract] [Full Text] [Related]
7. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
8. Workup for proteinuria.
Snyder S; John JS
Prim Care; 2014 Dec; 41(4):719-35. PubMed ID: 25439530
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of renal failure progression two years prior to dialysis.
Mazouz H; Kacso I; Ghazali A; El Esper N; Moriniere P; Makdassi R; Hardy P; Westeel PF; Achard JM; Pruna A; Fournier A
Clin Nephrol; 1999 Jun; 51(6):355-66. PubMed ID: 10404696
[TBL] [Abstract][Full Text] [Related]
10. [Progression factors in chronic kidney disease. Non-immunological mechanisms].
Fernández Fresnedo G; Sánchez Plumed J; Arias M; Del Castillo Caba D; López Oliva MO
Nefrologia; 2009; 29 Suppl 1():16-24. PubMed ID: 19675657
[TBL] [Abstract][Full Text] [Related]
11. The Remission Clinic approach to halt the progression of kidney disease.
;
J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
[TBL] [Abstract][Full Text] [Related]
12. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
[TBL] [Abstract][Full Text] [Related]
13. Improving the management of chronic kidney disease in Uruguay: a National Renal Healthcare Program.
Schwedt E; Solá L; Ríos PG; Mazzuchi N;
Nephron Clin Pract; 2010; 114(1):c47-59. PubMed ID: 19816043
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
15. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
Ahmed AK; Kamath NS; El Kossi M; El Nahas AM
Nephrol Dial Transplant; 2010 Dec; 25(12):3977-82. PubMed ID: 19820248
[TBL] [Abstract][Full Text] [Related]
16. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
[TBL] [Abstract][Full Text] [Related]
17. Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease.
Rosansky SJ
Am J Nephrol; 2012; 36(1):1-10. PubMed ID: 22699366
[TBL] [Abstract][Full Text] [Related]
18. The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies.
Goyache-Goñi B; Aranda-Lara P; Reyes-Engels A; Frutos-Sanz MA; Hernández-Marrero D
Nefrologia; 2013 Nov; 33(6):771-8. PubMed ID: 24241364
[TBL] [Abstract][Full Text] [Related]
19. Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease.
Ekart R; Ferjuc A; Furman B; Gerjevič Š; Bevc S; Hojs R
Ther Apher Dial; 2013 Aug; 17(4):363-7. PubMed ID: 23931872
[TBL] [Abstract][Full Text] [Related]
20. Progressive chronic kidney disease in primary care: modifiable risk factors and predictive model.
Herget-Rosenthal S; Dehnen D; Kribben A; Quellmann T
Prev Med; 2013 Oct; 57(4):357-62. PubMed ID: 23783072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
